Intuitive's $450 million antitrust settlement cuts profit; adjusted earnings rise 25%

Intuitive sells and leases surgical robots, then earns money each time one is used. A da Vinci system generally sells for $0.6 million to $3.1 million, and the company earns $900 to $3,700 of instrument and accessory revenue per procedure, plus a yearly service fee of $95,000 to $225,000.¹ Revenue the company counts as recurring was about 85% of the second quarter's total. At September 30 it had 12,094 da Vinci systems installed, up 12% in a year, plus 1,152 Ion systems, its robot used in lung biopsies.² In 2025 it booked $10.06 billion of revenue and $3.03 billion of operating cash flow, and spent $540 million on equipment and buildings. That left about $2.49 billion of free cash flow, meaning cash from operations after capital spending.³

The 10-K names Johnson & Johnson, Karl Storz, Medicaroid and Medtronic among its robotic-surgery rivals. Reuters reported in July that Johnson & Johnson had entered the American robotic-surgery market after its device won marketing authorization.¹ Intuitive makes a significant majority of its instruments and accessories in Mexico, so tariffs bear on its margins. Its June 10-Q said hospital customers would stay cautious about capital spending.² The same filing said the end of enhanced Affordable Care Act premium subsidies modestly hurt American procedure growth, and that American bariatric (weight-loss) procedures fell by a high single digit.³

Intuitive began 2026 guiding to da Vinci procedure growth of 13% to 15% for the full year, after 17% growth in the fourth quarter of 2025. By its July report the full-year range was 13.5% to 15.5%.¹ After that July report the shares slid about 13%, as Reuters reported the company had warned that changes to Obamacare plans could dampen demand for surgeries.² The stock then recovered, rising 15% from $376.75 on September 15 to $433.26 on October 19, while the XLV health-care fund rose about 4.8%.³

The case being settled, In re: da Vinci Surgical Robot Antitrust Litigation, is the hospital class action that began with a complaint by Larkin Community Hospital filed on May 20, 2021. The court certified the class on March 31, 2025, and set trial for September 14, 2027.¹ Along the way the court found that Intuitive holds monopoly power in an instrument aftermarket, then granted Intuitive's motion for reconsideration on July 30, 2024.² Two other antitrust suits are separate. A trial court found for Intuitive on all of Surgical Instrument Service Company's claims, and that appeal was argued on June 25, 2026; Restore Robotics Repairs, whose suit was dismissed, filed its appeal reply brief on July 6, 2026.³

Intuitive reached the settlement in October 2026, after a mediation. It will make a one-time payment of $450 million and accept mutually agreed injunctive relief, meaning a court order on how it does business, without admitting liability or wrongdoing.¹ It booked the full $450 million as a selling, general and administrative expense in the third quarter. After tax the charge is $347 million, or $0.99 a share, which implies a tax saving of about $103 million.² The deal still needs preliminary and final court approval. The company says there is no assurance the court will approve it or that class members will not object.³

Measured against the company, the payment is modest. It equals 6.6% of the $6.80 billion of cash and investments at September 30, about 15% of one quarter's revenue and about 18% of 2025 free cash flow.¹ After tax it is about 0.24% of a market value of about $143 billion, using the quarter's 351.6 million average diluted shares and the $407.99 after-hours price.² Cash and investments exceed total liabilities of $3.23 billion by about $3.57 billion, so debt ratios and interest coverage are not a concern here.³

For its money and the conduct limits, Intuitive would end, if the court approves the deal, a certified class action that was headed to trial in 2027, along with the risk of a larger loss there. The hospitals in the class get a cash payment instead of waiting for that trial.¹ What the conduct limits require is the open question. Instruments and accessories brought in $1.80 billion of the quarter's $3.05 billion of revenue, so any limit on how Intuitive controls instruments could matter more over time than the one-time cash.² The release describes only the class action as settled; the two appeals above were still pending in the June 10-Q.³

Reported net income fell to $523 million from $704 million. Adjusted net income rose to $1.05 billion from $867 million.¹ The $532 million gap between the two comes from items the adjusted figure leaves out: litigation charges, stock pay of $216 million in the quarter, amortization of acquired intangibles, acquisition items and tax adjustments. Stock pay is a real cost that the company itself says will stay significant and recurring for the foreseeable future.² Adding back the $0.99 settlement charge, reported earnings would have been about $2.48 a share, up about 27% from $1.95.³ Two loose ends remain. Total litigation charges were $454.9 million, about $4.9 million more than the settlement, and the per-share table shows $1.00 for litigation against the $0.99 in the text.⁴ The adjusted $3.00 also includes a $22 million, or $0.06 a share, benefit from refunds of tariffs paid in earlier periods; the second quarter carried a similar $0.08 and the year-earlier quarter none. Without it, adjusted earnings were $2.94, up 22.5% from $2.40.⁵

The business underneath kept growing. Revenue rose 22% to $3.05 billion, instruments and accessories rose 18% to $1.80 billion, and systems revenue rose to $769 million from $590 million.¹ Intuitive placed 546 da Vinci systems, up about 28% from 427, including 315 da Vinci 5 units. Of those placements, 291 were operating leases and 160 were paid for by usage.² Da Vinci procedures grew about 14% and Ion procedures about 31%. In the second quarter da Vinci growth had been 15%.³ Adjusted operating income rose to $1.27 billion from $976 million, about 42% of revenue. Reported operating income fell to $593 million from $760 million, about 19% of revenue.⁴

Intuitive bought back 7.8 million shares for $2.94 billion in the quarter, an average of about $377 a share. In the second quarter it paid an average of $438.68.¹ Cash and investments fell $1.83 billion to $6.80 billion, from $8.63 billion at June 30, mainly because of buybacks and equipment purchases. Interest and other income dropped to $75.8 million from $95.5 million a year earlier.² Operating cash flow was $1.97 billion in the first half of 2026. The board had about $4.7 billion of buyback authority left at June 30, before the third-quarter purchases.³

Buybacks are shrinking the share count: diluted shares averaged 351.6 million in the quarter, against 361.8 million a year earlier. At June 30, before the 7.8 million shares bought back in the third quarter, there were 353.9 million shares outstanding, plus 4.7 million options with an average exercise price of $214.99, 4.6 million unvested restricted stock units and 0.2 million performance units, or about 363 million on a fully diluted basis.¹ Those counts are as of June 30, 2026, so they do not yet reflect the 7.8 million shares Intuitive repurchased in the third quarter.² On July 21, 2026 Intuitive registered 5,000,000 more shares for its employee stock plan, none of them issued at the time.³ Executive Chair Gary Guthart sold 10,000 shares at $400 in August 2026; the June-quarter 10-Q says he had adopted a preset Rule 10b5-1 trading plan.⁴

Intuitive's 2026 targets are its own goals, not results. It now expects da Vinci procedures to grow about 14% to 15% for the full year and to land closer to the midpoint, against 13.5% to 15.5% in July; the midpoint stays at 14.5%, but the top of the range came down.¹ It raised its full-year adjusted gross margin range to 68.7% to 69.3%, from 68.0% to 69.0%, with tariffs now an estimated 0.9% of revenue instead of 1.0%, and kept adjusted operating expense growth at 11% to 13%. The margin range assumes current tariffs stay in place through year-end.²

Intuitive released the results on October 20, 2026.¹ ISRG closed at $433.26 on October 19 and traded at $437.85 a minute before the close on October 20; after the release it traded at $407.99 after hours, about 6.8% below that last regular-session price and 5.8% below the October 19 close, while SPY was up 0.5% from its October 19 close.² That price is still about 8% above the $377 average Intuitive paid for its own shares last quarter, and above the $376.75 close on September 15.³ The roughly 6.8% after-hours drop is far larger than the settlement's 0.24% after-tax cost, but no source explains it; slower third-quarter procedure growth and the undisclosed conduct limits in the settlement are both candidates.⁴

At $407.99 the shares trade at about 38 times $10.83 of trailing adjusted earnings per share.¹ That sum is $8.30 year to date through September 2026, plus $2.53 in the fourth quarter of 2025.²

The strongest bull case: Intuitive settled a certified class action for a sum its cash covers many times over, while revenue grew 22%, system placements rose about 28% and Ion procedures grew about 31%.¹ It also raised its margin range, and it is buying back stock at about $377 a share, below where the shares traded even after the drop.²

The strongest bear case, in order of weight. First, growth is fading: da Vinci procedures grew 17% in the fourth quarter of 2025, then 15% in the second quarter and about 14% in the third.¹ Second, the conduct limits are undisclosed and could touch instruments and accessories, which brought in $1.80 billion of the quarter's $3.05 billion of revenue.² Third, American demand faces lost insurance subsidies, falling bariatric volumes, cautious hospital budgets and a field of rivals that includes Johnson & Johnson.³ Fourth, the adjusted figures exclude $216 million of quarterly stock pay and include refunds of earlier tariffs ($0.06 a share this quarter, $0.08 in the second), and cash fell $1.83 billion in one quarter, mainly on buybacks.⁴

Our view is that the settlement is a manageable one-time cost and the stock's real test is growth. That view is wrong if the court rejects the deal, if the conduct limits turn out to restrict instrument sales, or if the January report shows growth falling well below the full-year 2026 range of 14% to 15%.¹ Our cash-flow call rests on a simple bridge: operating cash flow was $1.97 billion in the first half, and cash and investments fell only $1.83 billion in a quarter when buybacks alone took $2.94 billion.² The dates to watch: the third-quarter 10-Q, which should give the quarter's cash flow; the court's preliminary approval ruling, date unknown; a ruling on the Surgical Instrument Service Company appeal argued June 25, 2026; and the fourth-quarter report, which last year came on January 22 with the new year's outlook.³

The release says the deal includes mutually agreed injunctive relief but does not describe it.¹ We do not know whether it changes how Intuitive sells, services or limits the use of its instruments, which brought in $1.80 billion of the quarter's $3.05 billion of revenue.²

The filings give no hearing date for preliminary or final approval and do not say when the $450 million will be paid.

The release gives the change in cash and investments but not the quarter's operating cash flow or capital spending, so third-quarter free cash flow is not known until the 10-Q.

Total litigation charges were $454.9 million, about $4.9 million more than the settlement, and the release does not say what the extra amount covers or why the per-share table shows $1.00 against $0.99 in the text.

The Surgical Instrument Service Company appeal was argued on June 25, 2026, and Restore Robotics Repairs filed its reply brief on July 6, 2026; the filings give no ruling or decision date for either.

The release does not split third-quarter procedure growth between the United States and other countries, so it is not yet clear where the slowdown came from.

The board had about $4.7 billion of authority at June 30; the release does not say how much is left after the $2.94 billion spent in the third quarter, or whether the board added more.